QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (33) Citing Articles via Google Scholar Google Scholar Articles by Davis, F. G. Articles by Surawicz, T. Search for Related Content PubMed PubMed Citation

Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups

Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL 60612

² Address correspondence and reprint requests to Faith G. Davis, Professor and Director, Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, 2121 West Taylor St., Chicago, IL 60612.

Abstract

Prevalence rates are used to supplement descriptions of disease and are unavailable for all primary brain tumors in the United States. Data from two population-based tumor registries were obtained from the Central Brain Tumor Registry of the United States and used to compute age-specific incidence rates (1985-1994) and survival curves for further use in a statistical model to estimate prevalence rates. Prevalence rates were then used to estimate the number of individuals living with a brain tumor diagnosis in the U.S. population for the year 2000. The overall incidence rate in these regions is 13.8 per 100,000 with 2-, 5-, and 10-year survival rates of 58%, 49%, and 38%, respectively. The prevalence rate for all primary brain tumors is 130.8 per 100,000 with approximately 350,000 individuals estimated to be living with this diagnosis in the United States in 2000. The prevalence rate for malignant tumors, 29.5 per 100,000, is similar to previous reports. The prevalence rate for benign tumors, 97.5 per 100,000, is new. Unlike incidence data, the proportion (and expected number) of existing benign tumors (75%, 267,000) is considerably greater than that for malignant tumors (23%, 81,000), reflecting the better prognosis of benign tumors diagnosed in individuals younger than 60 years old. These data underscore the impact of primary brain tumors in the U.S. health care system and emphasize the need for quality-of-life considerations, particularly for those long-term survivors of benign tumors.

This article has been cited by other articles:

				C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X.-x. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin, and J. S. Yu Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients Cancer Res., July 15, 2008; 68(14): 5955 - 5964. [Abstract] [Full Text] [PDF]

				J. M. Royal and B. S. Peterson The risks and benefits of searching for incidental findings in MRI research scans. J. Law Med. Ethics, June 1, 2008; 36(2): 305 - 314. [PDF]

				J. R. Schubart, M. B. Kinzie, and E. Farace Caring for the brain tumor patient: Family caregiver burden and unmet needs Neuro-oncol, February 1, 2008; 10(1): 61 - 72. [Abstract] [Full Text] [PDF]

				A. F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M. A. Tichomirowa, and A. Beckers High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4769 - 4775. [Abstract] [Full Text] [PDF]

				S. F. Hussain, D. Yang, D. Suki, K. Aldape, E. Grimm, and A. B. Heimberger The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses Neuro-oncol, July 1, 2006; 8(3): 261 - 279. [Abstract] [Full Text] [PDF]

				C. J. Wheeler, A. Das, G. Liu, J. S. Yu, and K. L. Black Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination Clin. Cancer Res., August 15, 2004; 10(16): 5316 - 5326. [Abstract] [Full Text] [PDF]

				J. S. Yu, G. Liu, H. Ying, W. H. Yong, K. L. Black, and C. J. Wheeler Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma Cancer Res., July 15, 2004; 64(14): 4973 - 4979. [Abstract] [Full Text] [PDF]

				C. J. Wheeler, K. L. Black, G. Liu, H. Ying, J. S. Yu, W. Zhang, and P. K. Lee Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality J. Immunol., November 1, 2003; 171(9): 4927 - 4933. [Abstract] [Full Text] [PDF]

				M. Wrensch, Y. Minn, T. Chew, M. Bondy, and M. S. Berger Epidemiology of primary brain tumors: Current concepts and review of the literature Neuro-oncol, October 1, 2002; 4(4): 278 - 299. [Abstract] [PDF]